Pharmaceuticals

With Olav Hellebø at the helm, Exonate is advancing a topical eye drop that could end painful eye injections for millions with diabetic retinopathy.

With a fresh €6.3M, Munich-based smartbax is developing antibiotics that make bacteria self-destruct, offering new hope against a growing global crisis.

New data on at-home lecanemab injections signals a major shift in Alzheimer's care, promising greater convenience and access for patients and caregivers.

A new partnership between Finland's Orion Pharma and India's Shilpa Medicare aims to bring a lower-cost cancer therapy to Europe, challenging a blockbuster drug.

With FDA Priority Review for its at-home therapy Enspryng, Roche is signaling a major disruption in the lucrative Thyroid Eye Disease market.

Health Canada's approval of a generic Wegovy promises to slash costs and expand access, shifting the landscape for patients and the healthcare system.

A new chemo-free combo from Genmab and AbbVie shows a 60% reduction in disease progression for a tough-to-treat blood cancer, setting a new standard.

With FDA clearance, Gain Therapeutics' GT-02287, an AI-discovered drug, advances to Phase 2, offering a new hope to modify Parkinson's, not just its symptoms.

After a fierce campaign reversed drastic cuts to Florida's HIV drug program, thousands can breathe again. But a new cap and missing aid reveal a fragile victory.

An investor rights law firm is investigating the $929M sale of Theravance Biopharma, asking if shareholders are getting a fair deal or if the board failed them.

A wave of precision drugs for Nephrotic Syndrome is set to transform patient lives and a quiet $400M market, revealing a major shift in pharma strategy.

Artelo Biosciences advances a novel non-opioid painkiller, using AI to map its effects and potentially revolutionize how we treat chronic pain.

Evommune halts a key drug trial for chronic hives but leans on a strong cash position and a diversified pipeline to navigate the setback.

A new 'radical collaboration' between top cancer centers is leveraging recent drug breakthroughs to develop combination therapies for pancreatic cancer's deadliest mutation.

AMR Clinical's acquisition of ClinOhio isn't just about growth; it's a strategic move in a booming market, promising faster drug development for sponsors.

A new patent for a non-hallucinogenic compound positions Clearmind Medicine to disrupt the multi-billion dollar market for addiction and compulsive disorders.

A new patent in South Korea for a novel breast cancer vaccine offers a potential paradigm shift from treatment to prevention, but the road from patent to patient is long.

With its fibromyalgia drug now on the market, Tonix is expanding its use to MDD, targeting disturbed sleep in a novel approach for millions of patients.

With a new FDA Fast Track designation, Satellos Bioscience aims to accelerate its unique muscle-regenerating drug for Duchenne, a strategy that could sidestep genetic limitations.

BioCryst is closing its discovery labs to save millions, betting on external partnerships for its next big drug. But what is the hidden cost of this pivot?